The UK’s first high-containment Category 3 robotic laboratory is now supporting its first commercial project, marking a major milestone in automated scientific research. The facility, being delivered through a collaboration between the Liverpool School of Tropical Medicine (LSTM) and the Infection Innovation Consortium (iiCON), is designed to integrate advanced robotic systems and AI-enabled workflows capable of handling infectious disease research at scale.
The inaugural project involves a partnership between Canadian biotech Eyam Health and iiDiagnostics (iiDX), working together to advance novel vaccine technologies using cutting-edge organoid platforms. This collaboration is the first commercial contract to emerge from the robotic laboratory, which has been supported by investment funds aimed at bolstering innovation in UK science infrastructure.
By enabling faster, more automated experimentation in a highly controlled setting, the lab is set to accelerate progress on life-saving vaccines and therapeutics. It also highlights how AI and robotics can reshape laboratory research, helping position the UK at the forefront of technological adoption in bioscience.
Read the full story here.
